The biologics safety testing market size, valued at USD 4.9 billion in 2025, is projected to reach USD 5.3 billion in 2026 and USD 9.4 billion by 2035, representing a CAGR of 6.6% during the forecast period 2026 to 2035. In terms of end-user, the pharmaceutical and biotechnology companies segment accounts for around 50% of the overall revenue share. North America is holding close to 40% of the market share due to its strong public and private investments, supportive regulations, and significant...

The global biologics API market size, valued at USD 70.4 billion in 2025, is projected to reach USD 78.4 billion in 2026 and USD 153.8 billion by 2035, representing a CAGR of 8% during the forecast period, 2026 to 2035. Several large biopharmaceutical players, such as Novartis, Pfizer, Roche and Eli Lilly are supporting the active pharmaceutical ingredient manufacturing in their in-house API manufacturing facilities for the efficient production of various biologics. In the future, hybrid manufac...

The global cancer biologics market size, valued at USD 189 billion in 2025, is projected to reach USD 210 billion in 2026 and USD 442 billion by 2035, with a CAGR of 8.6% during the forecast period 2026 to 2035. In the past few years, drug-based interventions (including biologics and small molecules) have observed a rapidly expanding pipeline for various types of cancer. The increased focus on personalized cancer biologics therapy market has garnered the interest of several pharmaceutical compan...

he broader focus will be on the development of tailored therapeutic drugs, including gene therapies, companion animal vaccines and recombinant proteins that can address animal’s unique needs.For instance, in February 2025, Bharat Biotech (India) announced that its Biolumpivaxin (vaccine for lumpy skin disease) has received the Central Drug Standards Control Organization license for cattle’s and buffaloes. As more market players continue to develop advanced biologics, it is expected that vete...

The biologics fill finish manufacturing market, valued at USD 4.4 billion in 2025, is projected to reach USD 4.7 billion in 2026 and USD 8.4 billion by 2035, representing a CAGR of 6.71%, during the forecast period 2026 to 2035. Through our new market research study, we have identified the key market trends, competitive landscape, market forecast and opportunity for biologics fill finish service providers. The biologics fill finish manufacturing market growth over the next decade is expected to...

The global subcutaneous biologics market, valued at USD 250.6 billion in 2025, is projected to reach USD 267.6 billion in 2026 and USD 233.0 billion by 2035, during the forecast period 2026 to 2035. In the first quarter of 2024, nine biologics received the USFDA approval. This paradigm shift observed towards the preference of biologics can be attributed to their ability to offer targeted treatment (with minimal drug interactions) due to their specific binding and metabolic pathways. The exhausti...

The global biologics market size is worth around $411 billion in 2024 and is expected to reach $962 billion by 2035, representing a higher compounded annual growth rate (CAGR) of 8.04% during the forecast period. According to the World Health Organization report, nearly 422 million people across the globe are suffering from diabetes. Moreover, nearly 41 million people die annually due to non-communicable diseases, which is equivalent to around 74% of all deaths occurring across the globe. The ri...

The global retinal biologics market size is currently valued at $ 25.65 billion and is poised to reach $ 57.47 billion by 2035, it is estimated to grow at a CAGR of 7.61%, during the forecast period. There has been a surge in the number of patients suffering from various retinal diseases, such as diabetic retinopathy, glaucomatous retinal degeneration and age-related macular degeneration. As per the World Health Organization, in 2023, nearly 2.2 billion people have near, or distance vision impai...

The global biologics contract research organization market size, valued at USD 27.0 billion in 2024, is projected to reach USD 36.0 billion in 2025 and USD 126.0 billion by 2035, representing a CAGR of 13% during the forecast period. According to the biologics contract research organization market report, presently the antibodies segment holds the highest share (45%), and the trend is likely to remain unchanged. Among these, the clinical segment holds the largest biologics contract research orga...

The China biologics contract manufacturing market, valued at USD 5.7 billion in 2025, is projected to reach USD 6.5 billion in 2026 and USD 15.5 billion by 2035, with a 10.2% CAGR during the forecast period 2026 to 2035. It is worth noting that till date, over 25 biologics and biosimilar products have been approved in China. In addition, close to 1,000 clinical trials, investigating a variety of biologics and biosimilars for treating a diverse range of diseases, are presently underway in this re...

The global rare kidney diseases market size, valued at USD 3.4 billion in 2025, is projected to reach USD 4.9 billion in 2026 and USD 21.7 billion by 2040, with a CAGR of 11.2% during the forecast period 2026 to 2040. According to the Orphan Drug Act, in the United States, diseases are considered rare when they affect less than 200,000 Americans. However, according to the European Union, the prevalence threshold is 5 per 10,000 people. In June 2026, AstraZeneca received Priority Review designati...

The global inflammatory bowel disease treatment market size, valued at USD 22.6 billion in 2025, is projected to reach USD 24.3 billion in 2026 and USD 43.8 billion by 2035, representing a CAGR of 6.8% during the forecast period 2026 to 2035. Close to 30 drugs are currently approved for the treatment of inflammatory bowel disease. However, these drugs often fail to achieve sustained remission in a significant subset of patients and frequently lose effectiveness over time. Many drugs are associat...

The North America cancer metabolism based therapeutics market, valued at USD 1.32 billion in 2025, is projected to reach USD 1.78 billion in 2026 and USD 12.03 billion by 2035, with a CAGR of 23.7% during the forecast period 2026 to 2035. North America continues to report a substantial oncology disease burden, creating sustained demand for therapies that can address difficult-to-treat and genetically defined cancers. In the US alone, around 2.11 million new cancer cases and 626,140 cancer deaths...

The global ulcerative colitis market size, valued at USD 13.0 billion in 2025, is projected to reach USD 14.0 billion in 2026 and USD 25.7 billion by 2035, representing a CAGR of 7.0% during the forecast period 2026 to 2035. Based on route of administration, the subcutaneous route dominates (more than 40%) the current market; this trend is unlikely to change in the future. With respect to distribution channels, hospital pharmacies are expected to capture most of the future ulcerative colitis mar...

The global Crohn’s disease market size, valued at USD 9.6 billion in 2025, is projected to reach USD 10.3 billion in 2026 and USD 18.1 billion by 2035, representing a CAGR of 6.5% during the forecast period 2026 to 2035. Based on the route of administration, the subcutaneous route dominates (more than 40%) the future market (2035). The rising prevalence of Crohn’s disease represents a major market opportunity within this domain. Notably, in 2023, an estimated 1 million patients were living w...

The Europe cancer metabolism based therapeutics market, valued at USD 0.82 billion in 2025, is projected to reach USD 1.12 billion in 2026 and USD 8.54 billion by 2035, with a CAGR of 25.3% during the forecast period 2026 to 2035. In terms of type of modality, small molecules are expected to account for the largest market share in 2026; this trend is unlikely to change in the future. With respect to route of administration, oral route (close to 85%) is expected to dominate the market in 2035. Th...

The global automated rapid microbiology testing platforms market, valued at USD 48.7 million in 2025, is projected to reach USD 51.7 million in 2026 and USD 108.7 million by 2035, representing a CAGR of 8.6% during the forecast period 2026 to 2035. In terms of type of modality, biologics accounts for the highest share (over 60%) of the current market. With respect to type of offering, consumables dominate the current market.

The global AI in drug discovery market, valued at USD 6.0 billion in 2025, is projected to reach USD 8.6 billion in 2026 and USD 25.0 billion by 2035, representing a CAGR of 12.6% during the forecast period 2026 to 2035. In terms of application, lead optimization holds the largest share (around 50%) of the current market. With respect to the type of AI technology, machine learning dominates the current market, accounting for 40% revenue share.

The heart failure drugs market, valued at USD 7.84 billion in 2025, is projected to reach USD 9.19 billion in 2026 and USD 12.31 billion by 2035. Heart failure is a chronic condition in which the heart is unable to pump sufficient blood into different organs. Further, in order to mitigate the growing incidence, pharmaceutical companies have developed heart failure drugs that can target wide range of conditions, such as managing fluid build-up, improving cardiac contractility, controlling blood p...

The GLP-1 receptor agonist market size, valued at USD 78 billion in 2025, is projected to reach USD 101.4 billion in 2026 and USD 180 billion by 2035, representing a CAGR of 6.6% during the forecast period 2026 to 2035. In recent years, there has been a notable shift in consumer lifestyles driven by the growing influence of social media, celebrity endorsements and direct-to-consumer advertising. This has led to a surge in the demand for weight loss and type 2 diabetes treatment solutions, which...